IceCure Medical announced the departure of long‑time Chief Financial Officer Ronen Tsimerman, who will stay on until a successor is appointed. Tsimerman, who joined the company in 2017, has overseen the Nasdaq listing, the ICE3 study fundraising, and the FDA clearance of the ProSense cryoablation system.
The company is actively searching for a new CFO with experience commercializing disruptive medical technologies. Several candidates have advanced to interview stages with the board, and an interim CFO will be appointed to maintain continuity during the transition.
The CFO exit comes shortly after IceCure secured FDA marketing clearance for its ProSense system for low‑risk breast cancer on October 3, 2025, and after a $10 million rights offering that closed on July 28, 2025. The rights offering, which was twice oversubscribed, helped strengthen the company’s cash position and provided funds to repay a bridge loan and support general corporate purposes.
Management highlighted Tsimerman’s contributions to the company’s growth trajectory. CEO Eyal Shamir said Tsimerman “played a pivotal role in achieving key milestones, from the Nasdaq listing to the ProSense clearance, and his departure marks the end of a significant chapter in IceCure’s history.”
While the CFO transition is routine, analysts note that IceCure faces ongoing financial challenges, including negative operating margins and declining revenue growth. The company’s recent regulatory win and capital raise provide a short‑term boost, but the broader financial picture remains a concern for investors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.